KRAS and neoplasm: Targeted therapies such as Sotorasib—a tyrosine kinase inhibitor—selectively binding KRAS G12C mutated proteins have been reported to be effective in KRAS G12C mutated lung cancer patients with good tumor responses and better progression-free survival of patients.